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isk factors for type 2 diabetes and cardiovascular disease
CVD) often cluster, including obesity (particularly central),
nsulin resistance, hyperglycemia, dyslipoproteinemia, and
ypertension. These conditions can also occur in isolation,
nd they are exaggerated by physical inactivity and smoking.
ince each of these factors increases risk of CVD, the
oncept of global cardiometabolic risk (CMR) (Fig. 1) is of
alue (1). Lipoprotein abnormalities, including elevated
riglycerides, low HDL cholesterol, and increased numbers
f small dense LDL particles, are common findings in
atients with CMR. Clinical entities with increased CMR
nclude type 2 diabetes, familial combined hyperlipidemia,
amilial hypoalphalipoproteinemia, and polycystic ovary
yndrome (2). These disorders often share the CMR char-
cteristics of central obesity, insulin resistance, dyslipopro-
einemia, and hypertension.
There are stringent lipid treatment goals for patients with
type 2 diabetes or CVD; however, guidelines for treatment
of dyslipoproteinemia in high-risk subjects without diabetes
or CVD are less intense and are based primarily on LDL
cholesterol concentrations, with non-HDL concentrations a
secondary consideration in some subjects. Numerous trials
have demonstrated that therapies (primarily statins) directed
at LDL cholesterol lowering clearly reduce risk of CVD
events in patients with diabetes and in those without
diabetes but with other CVD risk factors; yet, a number of
questions remain. Even with adequate LDL cholesterol
lowering, many patients on statin therapy have significant
residual CVD risk. It is unclear whether lipoprotein param-
eters other than LDL or non-HDL cholesterol provide
clinically significant additional prognostic information re-
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April 15, 2008:1512–24 Consensus Conference Reportiveness of therapy, or indicate more appropriate treatment
argets. Many patients with CMR or diabetes have relatively
ormal levels of LDL cholesterol but increased numbers of
mall dense LDL particles and other atherogenic lipopro-
eins. Some have advocated that assessment of other li-
oprotein parameters might be more helpful than assess-
ent limited to LDL or non-HDL cholesterol in these
opulations. In addition, treatment targets and the best
pproach for CVD risk reduction in this population need to
e better defined.
To address these issues, the American Diabetes Associ-
tion convened a consensus development conference on
8–20 July 2007 focusing on lipoprotein management in
atients with CMR. Following presentations of invited
peakers and in-depth discussions, a seven-member panel of
xperts in endocrinology and metabolism, cardiology, epi-
emiology, and public health developed a consensus posi-
ion, addressing the following questions in relation to
atients with CMR:
. To what extent do lipoproteins contribute to CVD?
. What are the clinically important lipoprotein parameters?
. In the evaluation and treatment of patients with lipopro-
tein abnormalities, are there other factors that should be
considered?
. What are the principles and objectives of treatment of
lipoprotein abnormalities?
. What new information would help improve lipoprotein
management?
o What Extent Do Lipoproteins
ontribute to CVD?
VD (defined here as coronary artery disease [CAD],
igure 1. Factors Contributing to Cardiometabolic Riskerebrovascular disease, and peripheral arterial disease) is ahe major cause of morbidity and mortality in the Western
orld. This is true despite dramatic improvements in
herapy over the last few decades. The prevalence of CVD
nd its associated morbidity is high. Importantly, the initial
resentation of CAD in up to one-third of patients is
udden death. Thus, a detailed knowledge of the athero-
clerotic process is necessary in order to design interventions
o prevent atherosclerosis or reduce its rate of progression
nce the process has been initiated.
Lipoproteins are the particles that transport cholesterol
nd triglycerides, two compounds essential to cell structure
nd metabolism that are not soluble in aqueous solutions.
ipoproteins are comprised of proteins (apolipoproteins),
hospholipids, triglycerides, and cholesterol. The classes of
ipoproteins vary in the major apolipoproteins present and
he relative contents of all of the lipid components.
Chylomicrons are primarily triglyceride-bearing lipopro-
eins produced after a meal during the process of lipid
bsorption. VLDLs are produced by the liver with a primary
unction of supplying free fatty acids to tissues and are
ormally the predominant carriers of circulating triglycer-
des. LDLs are by-products of VLDL metabolism and, in
he normal state, are the primary carriers of plasma
holesterol. Chylomicrons, VLDL, and LDL all carry
poB, among other apolipoproteins. HDLs carry apoAI
nd apoAII. Nascent HDL particles are produced by the
iver and intestine and then mature and become enriched
ith other apolipoproteins and lipids by exchanges with
hylomicrons and VLDL. The size and density of the
ipoprotein categories vary, from the largest and least
ense chylomicrons to the smallest and most dense HDL.
ithin each category, there is also a spectrum of particles
hat vary in size, density, and relative proportions of lipid
nd protein.
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Consensus Conference Report April 15, 2008:1512–24Atherosclerosis is a form of chronic inflammation result-
ng from complex interactions between modified lipopro-
eins, monocyte-derived macrophages, components of in-
ate and adaptive immunity, and the normal cellular
lements of the arterial wall. This process can ultimately
ead to the development of complex lesions or plaques that
rotrude into the arterial lumen, causing abnormal flow
atterns and clinical symptoms such as angina or claudica-
ion. In addition, vulnerable areas within plaques can
upture or erode, leading to intravascular thrombosis result-
ng in the acute clinical complications of myocardial infarc-
ion and stroke.
entral Role of LDL in Atherogenesis
mong the many contributing factors, elevated cholesterol
evels play a dominant role in both the initiation and
rogression of atherosclerosis, as well as in the clinical
onsequences such as myocardial infarction, stroke, periph-
ral vascular disease, and heart failure. Although a myriad of
ifferent genetic and environmental factors have been iden-
ified that modulate lesion formation in animal models,
therogenesis will not occur in these models in the absence
f greatly elevated plasma cholesterol levels (800 mg/dl)
xcept by direct arterial injury. Hypercholesterolemia also
ppears to be obligatory for atherogenesis in humans, but in
umans, where lesion formation usually occurs over many
ecades, the threshold level of plasma total cholesterol that
ust be exceeded to produce clinically relevant disease
ppears to be much lower than that in animal models.
therosclerotic clinical events are uncommon in humans
ith lifelong very low plasma cholesterol levels (3). In
eneral, however, there appears to be a curvilinear relation-
hip between increasing plasma cholesterol and increasing
ncidence of CVD.
The dramatic success of cholesterol-lowering therapy
ight suggest that low cholesterol levels would be all that is
equired to prevent the development of atherosclerotic
isease or halt or reverse established disease. This might be
rue if plasma cholesterol concentration could be reduced to
ery low levels long before the usual time of development of
linical disease. However, available hypolipidemic therapy
ay not lower cholesterol levels to very low values in all
atients. In addition, drug therapy is often initiated only
fter clinical disease is noted, and such therapy may not be
ufficient to prevent the progression of atherosclerosis.
The totality of evidence overwhelmingly supports the
entrality of elevated plasma cholesterol levels as a predictor
f the development of atherosclerosis, though a complex set
f genetic and environmental factors strongly influences the
xtent of atherogenesis and the expression of clinical events
t any given plasma cholesterol level. It must be recognized,
owever, that it is lipoproteins that interact with the arterial
all and set in motion the cascade of events that leads to
therosclerosis. Measurements of total cholesterol are indi-
ect estimates of the lipoproteins that transport the bulk of lholesterol in plasma and are the most atherogenic. In most
ircumstances, these are LDLs; however, in patients with
MR, VLDL and other apoB100-containing lipoproteins
lso may contribute to atherosclerosis.
Experimental studies directly support the central role of
DL in atherogenesis. Current concepts suggest that higher
lasma levels of LDL lead to increased transport into the
ntima, where LDL becomes bound to proteoglycans,
reatly prolonging its residence time. This makes LDL
usceptible to a variety of modifications, including oxida-
ion, enzymatic modification, nonenzymatic glycation, ag-
regation, and immune complex formation. All of these lead
o enhanced macrophage uptake, foam cell formation, and
nitiation of the cascade of events resulting in progression of
he atherosclerotic lesion.
The LDL receptor regulates plasma LDL levels. When
uman fibroblasts are grown in cell culture, they take up
edia LDL via the LDL receptor pathway until sufficient
holesterol is internalized to meet cellular needs, leading to
he downregulation of LDL receptors. The amount of LDL
holesterol that is needed in such cultures is only 2.5 mg/dl.
ecause there is a 10:1 gradient between plasma and
nterstitial fluid LDL levels, this implies that a plasma level
f 25 mg/dl LDL cholesterol would be sufficient to supply
eripheral cholesterol needs (4). Indeed, examination of
lasma LDL cholesterol levels in a variety of nonhuman
pecies reveals that their levels cluster around this value.
uman newborns have similarly low LDL cholesterol
alues, in the range of 40–50 mg/dl. In contrast, healthy
dult LDL cholesterol levels are 3–4 times higher (5).
eople with heterozygous mutations in the LDL receptor
ave LDL cholesterol levels two times normal levels at birth
nd many develop CAD by age 50. Children homozygous
or this disorder have LDL cholesterol levels 10-fold higher
han normal and will, if untreated, have CAD in the first
ecade of life (4). These data strongly suggest that high
evels of LDL cause atherosclerosis, as well as the significant
ose-response relationship between atherogenic lipopro-
eins and development of disease.
Animal and human trials of dietary and pharmacological
nterventions that reduce LDL cholesterol are associated
ith stabilization and regression of atherosclerosis in pro-
ortion to the cholesterol lowering achieved, supporting the
alidity of “the lower the cholesterol the better” notion,
specially in individuals with established CVD. Theoreti-
ally, all humans should maintain “newborn” LDL choles-
erol levels of about 50 mg/dl to prevent atherosclerosis, and
hose with existing CVD should be treated to similarly low
evels. The lower limit to safe and effective cholesterol
owering has not been established. Individuals with genetic
utations causing lifelong very low LDL cholesterol levels
ppear not only to avoid CVD but also to be free of other
bnormalities that might conceivably be linked to their very
ow plasma cholesterol levels (6).
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April 15, 2008:1512–24 Consensus Conference Reporthe Role of Other Lipoproteins in Atherosclerosis
ther abnormalities in lipoprotein components have been
ypothesized to be involved in the atherosclerotic process.
here is a specific dyslipoproteinemia in individuals with
nsulin resistance—and exacerbated in those with diabetes—
haracterized by elevated VLDL, lower HDL cholesterol, and
ltered distributions of particles in all lipoprotein classes. The
ncrease in plasma VLDL, caused by both increased hepatic
roduction and decreased clearance, is paired with a shift in
article distribution such that there are higher levels of large
nd intermediate-sized VLDL particles. It is not clear to what
xtent these changes stimulate atherosclerosis or are simply a
arker of a more atherogenic milieu, since larger VLDLs are
sually not able to penetrate the endothelium to enter the
ascular wall. Individuals with benign hypertriglyceridemias
haracterized by large VLDL do not have increased risk of
VD. On the other hand, the smaller VLDLs and their
atabolic product, intermediate-density lipoproteins (IDLs),
an enter the subendothelial space and could contribute sub-
tantially to atherosclerosis. They may also increase prothrom-
otic factors, thus triggering CVD events.
Lower HDL cholesterol is consistently observed in individ-
als with CMR or diabetes, related in part to abnormalities in
LDL metabolism. HDL protects against atherosclerosis, in
art by virtue of its ability to promote reverse cholesterol
ransport from cells in the vessel wall to the liver for disposal.
t also has anti-inflammatory properties and can protect LDL
rom oxidation. Population studies and clinical trials of patients
n statin therapy have demonstrated a strong inverse associa-
ion between HDL cholesterol levels and CVD risk.
Alterations in the particle distribution within lipoprotein
lasses in patients with CMR or diabetes may be pertinent to
therosclerosis. Of particular relevance are changes observed in
he LDL fraction, with increased numbers of small dense LDL
articles. Smaller particles have increased endothelial perme-
bility, are more easily oxidized and glycated, and are more able
o bind to proteoglycans in the vessel wall.
hat Are the Clinically Important
ipoprotein Parameters?
o intervene to prevent, halt, or reverse atherosclerosis, it is
mportant to identify which lipoproteins, or lipoprotein
omponents, are most clinically relevant. This includes the
ollowing considerations: whether they can be easily, pre-
isely, and cost-effectively measured in a clinical setting;
hether there are readily available treatment strategies that
an alter them; and whether the treatment strategy is
ffective in reducing cardiovascular events.
DL Cholesterol
large body of research, ranging from molecular to population
tudies, indicates that elevated LDL cholesterol is a major
redictor of CVD, including in populations with CMR or oiabetes. Mean LDL cholesterol levels are similar in diabetic,
nsulin-resistant, and nondiabetic populations, but levels vary
idely among individuals within any population, due to a
ariety of genetic and environmental causes. In the UK
rospective Diabetes Study trial of patients with type 2
iabetes, LDL cholesterol was the most powerful risk factor
redicting cardiovascular risk (7). Data from several studies
uggest that elevated levels of LDL cholesterol may have even
ore adverse effects in individuals with insulin resistance and
iabetes than in individuals without insulin resistance or
iabetes (8). There do not appear to be meaningful sex
ifferences in the predictive value of elevated LDL cholesterol
n individuals with diabetes or CMR. Age effects have not been
horoughly examined in the diabetic population, although data
rom predominantly nondiabetic populations suggest that
DL cholesterol is not a strong predictor of CVD in the
lderly (9,10).
In addition to the robust data indicating the usefulness of
DL cholesterol as a predictor of CVD in individuals with
iabetes, there are a number of large randomized controlled
rials that have established that lowering LDL cholesterol in
ndividuals with diabetes or with multiple cardiovascular
isk factors lowers CVD event rates for both primary
11–14) and secondary prevention (15–21).
Despite the usefulness of LDL cholesterol for CVD pre-
iction on a population level, the measure may have limitations
or individual risk assessment. The reference method, beta
uantitation, is complex and expensive. LDL cholesterol is
ypically estimated using the Friedewald equation, but this
quation progressively underestimates LDL cholesterol as
riglyceride levels increase. Available “direct” methods to mea-
ure LDL cholesterol are not well standardized (22). Measure-
ent of LDL cholesterol (the cholesterol within LDL parti-
les) has been the standard approach to approximate LDL
evels. However, the cholesterol content of LDL particles
aries from person to person and is influenced by metabolic
bnormalities such as insulin resistance and hyperglycemia.
ence, measurement of LDL cholesterol may not accurately
eflect the true burden of atherogenic LDL particles, especially
n those with the typical lipoprotein abnormalities of CMR:
levated triglycerides, low HDL cholesterol, and increased
umbers of small LDL particles.
DL Particle Number
more accurate way to capture the risk posed by LDL may
e to measure the number of LDL particles directly using
uclear magnetic resonance (NMR) (23). Many cross-
ectional (24) and prospective (25–29) studies show that
DL particle number is a better discriminator of risk than
s LDL cholesterol.
The size of LDL particles can also be measured. As small
ense LDL particles seem to be particularly atherogenic
30), assessment of particle size has intuitive appeal. Both
DL particle concentration and LDL size are important
redictors of CVD (31). However, the Multi-Ethnic Study
f Atherosclerosis suggested that on multivariate analyses,
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Consensus Conference Report April 15, 2008:1512–24oth small and large LDL were strongly associated with
arotid intima-media thickness (24), while the Veterans
ffairs High-Density Lipoprotein Cholesterol Intervention
rial (VA-HIT) showed that both were significantly related
o coronary heart disease (CHD) events (28). The associa-
ion of small LDL and CVD may simply reflect the
ncreased number of LDL particles in patients with small
DL. Hence, it is unclear whether LDL particle size
easurements add value to measurement of LDL particle
oncentration.
Limitations of the clinical utility of NMR measurement
f LDL particle number or size include the facts that the
echnique is not widely available and that it is currently
elatively expensive. In addition, there is a need for more
ndependent data confirming the accuracy of the method
32) and whether its CVD predictive power is consistent
cross various ethnicities, ages, and conditions that affect
ipid metabolism.
ipoprotein(a)
ipoprotein(a) [Lp(a)], an apoB-containing LDL-like par-
icle with enhanced binding to intimal proteoglycans and
rothrombotic effect, also predicts CVD. There is little
vidence that insulin resistance or diabetes influences Lp(a)
oncentrations. The clinical utility of routine measurement
f Lp(a) is unclear, although more aggressive control of
ther lipoprotein parameters may be warranted in those
ith high concentrations of Lp(a).
on-HDL Cholesterol
on-HDL cholesterol (total cholesterol minus HDL cho-
esterol) reflects the concentration of cholesterol within all
ipoprotein particles currently considered atherogenic. The
dult Treatment Panel III (ATP III) proposed that in
ndividuals with hypertriglyceridemia (which would include
any with CMR or diabetes), non-HDL cholesterol levels
re a secondary goal of therapy after targeting LDL choles-
erol levels. Many studies have demonstrated that non-
DL cholesterol is a better predictor of CVD risk than is
DL cholesterol (33–35), and this may be especially true of
tatin-treated patients (36). Additional benefits of non-
DL cholesterol measurement are its lack of additional
xpense in patients already getting lipid panel measurements
nd that it can be calculated from nonfasting samples.
poB-100
poB is found in chylomicrons, VLDL, IDL, LDL, and
p(a) particles. Since each of these particles contains a
ingle apoB molecule, measurements of apoB represent the
otal burden of particles considered most atherogenic
37,38). ApoB measurements do not require a fasting
ample, and the assay has been standardized (39,40), but is
ot yet widely available. As with non-HDL cholesterol and
MR-based measurements of LDL particle number, ineveral epidemiological studies and in post hoc analyses of clinical trials, apoB has been found to be a better predictor
f CVD risk than LDL cholesterol (41,42), particularly the
n-treatment LDL cholesterol level (15,17,36,42). These
nalyses suggest that once LDL cholesterol is lowered, apoB
ay be a more effective way to assess residual CVD risk and
o determine the need for medication adjustments. How-
ver, not all studies agree: in some studies, apoB did not
utperform LDL cholesterol and non-HDL cholesterol as
isk predictors (44–46). Discrepancies between studies may
e due to the inclusion of different proportions of subjects
ith CMR. In individuals with CMR, the discrepancies
etween apoB, LDL cholesterol, and non-HDL cholesterol
re greater, suggesting that apoB may be a more useful risk
redictor among these individuals (47).
riglyceride-Rich Lipoproteins
n the fasting state, plasma triglycerides are primarily
ound in VLDL, so plasma triglyceride measurements are
sed as a surrogate measure of VLDL. Triglycerides are
univariate predictor of CVD in many studies but often
ot an independent predictor in multivariate analyses.
his may be because triglycerides are highly linked to
bnormalities in HDL and LDL and because of high
iological and laboratory variability. Similarly, there are
o clinical trial data establishing that lowering triglycer-
des in individuals with or without diabetes indepen-
ently leads to lower CVD event rates when one adjusts
or changes in HDL cholesterol.
Chylomicron remnants may be atherogenic in a manner
imilar to VLDL remnants. There is little population-based
vidence that chylomicron remnants are linked to CVD, but
everal studies show consistent elevations of chylomicron
emnants in individuals with familial combined hyperlipid-
mia and diabetes, conditions associated with atherosclero-
is. Measures of chylomicron remnants are not readily
vailable.
DL Cholesterol
DL cholesterol levels are strong inverse predictors of
VD events in both diabetic and nondiabetic populations
48,49). It has been difficult to determine whether raising
DL cholesterol independently reduces CVD events, be-
ause all interventions that raise HDL cholesterol also affect
he concentration of other lipoproteins (50). The VA-HIT
as conducted in a population that was largely comprised of
ndividuals with CAD and low HDL cholesterol, including
25 with diabetes. Therapy with gemfibrozil reduced CVD
vents, and a post hoc analysis showed a modest association
f the reduction in CVD with the extent of HDL increase
51). Strategies to raise HDL cholesterol remain a promis-
ng area of research that may be particularly valuable for
reventing CVD in individuals with CMR and diabetes.
easurements of HDL subfractions or apoA1 appear to
rovide little clinical value beyond measurements of HDL
holesterol (49).
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April 15, 2008:1512–24 Consensus Conference Reportn the Evaluation and Treatment of Patients
ith Lipoprotein Abnormalities, Are There
ther Factors That Should Be Considered?
n patients with lipoprotein abnormalities, good clinical
ractice calls for a comprehensive evaluation of their current
ascular health, factors contributing to the observed dysli-
oproteinemia, and other factors that may alter the global
isk of first or recurrent CVD event. The objectives of the
valuation are as follows: 1) to determine, to the extent
ossible, the magnitude of the future risk of CVD events; 2)
o identify the presence of prognostic factors that may be
odifiable; and 3) to establish a treatment plan both in
erms of scope and intensity. An integral part of this process
hould be the active involvement of the patient because a
etter informed patient is more likely to adhere to the
reatment plan.
A major objective of the risk evaluation is to ascertain the
atient’s current vascular health to determine whether the
atient already has CVD. Stratification by the presence or
bsence of clinical CVD is important for decisions about the
ype of intervention and its intensity. The presence of
o-called subclinical vascular disease may be determined by
easuring coronary calcification, carotid intima-media
hickness, or the ankle-brachial index. Patients with docu-
ented subclinical atherosclerosis are at increased CVD risk
nd may be considered candidates for more aggressive
herapy (52–54). Whether such tests improve prediction or
linical decision making in patients with diabetes or CMR
s unclear.
The presence and severity of other major prognostic
actors besides lipoprotein abnormalities should also be
scertained. Modifiable risk factors include high blood
ressure, smoking, hyperglycemia, obesity, improved dietary
abits, and physical inactivity. The main nonmodifiable
rognostic factors are age, sex, ethnicity, and family history;
ther risk factors such as chronic kidney disease may also be
resent. Two components of age contribute to the risk of
VD. The aging process per se leads to vascular changes in
manner similar to that associated with age-related changes
n other organs. Additionally, age is an indicator of duration
f exposure to adverse prognostic factors. For example, a
erson exposed to the toxic effects of a one pack/day
moking habit over 30 years is more likely to have smoking-
elated arterial lesions than another person who has smoked
ne pack/day for 3 years. Sex differences lead to an earlier
nset of CVD in men than in women by about 10 years.
oung men have more CVD than premenopausal women;
owever, women’s rates catch up with men’s after meno-
ause. There are racial differences in the prevalence of
ertain prognostic factors, such as increased rates of hyper-
ension in African Americans. Family history of premature
AD, especially in siblings, also is a powerful prognosticactor. aAdditional biomarkers (e.g., C-reactive protein [CRP],
brinogen, and homocysteine) have been evaluated to de-
ermine their prognostic significance; however, their inde-
endent predictive power and clinical utility are still unclear.
n particular, CRP is often elevated in people with CMR,
ut here, too, the utility of its measurement in individuals
lready known to be at high risk is unknown.
isk Assessment and Strategies
n Primary Prevention
ome global risk assessment tools estimate an individual’s
isk of a major coronary heart disease event (such as fatal or
onfatal myocardial infarction) over 10 years (55). There is
general consensus that a 10-year risk of 20% requires
ggressive intervention directed at the abnormal prognostic
actors. Those with a 10-year risk 20% are given inter-
entions based on the number and magnitude of their risk
actors. Although such tools are helpful, they underestimate
ifetime risk, especially in youth and women. Assessments of
ifetime global risk may be more valuable guides to treat-
ent in subjects at intermediate or low 10-year risk. Risk
ssessment models often have the limitation that continuous
rognostic factors are dichotomized, which reduces their
tatistical power. The American Diabetes Association has
eveloped a risk assessment model that addresses global risk
ver a longer time frame (30 years) and does not dichoto-
ize continuous risk factors (http://www.diabetes.org/
iabetesphd/default.jsp).
The treatment plan for primary prevention may include
ntihypertensive and glucose-lowering medications and life-
tyle interventions directed at smoking cessation, weight
oss, adverse dietary habits, and increased physical activity.
uch lifestyle interventions have major potential benefits on
ardiovascular health and are often overlooked. There is
trong scientific evidence for CVD risk reduction for anti-
ypertensive, lipid-lowering, and smoking cessation thera-
ies. An aggressive approach to prevent multiple comor-
idities is warranted. Disappointingly, a large proportion of
igh-risk individuals are not receiving optimal preventive
are or fail to adhere to treatment recommendations.
isk Assessment and Strategies
n Secondary Prevention
he prognostic factors for the secondary prevention of
VD include those for primary prevention but also include
everal related to myocardial injury. For example, myocar-
ial ischemia, left ventricular dysfunction, and ventricular
rrhythmias are powerful prognostic indicators after myo-
ardial infarction (MI). Treatments with lipid-lowering
herapy (statins), aspirin, -blockers, and ACE inhibitors
ave well-documented benefits in secondary prevention. In
ddition, antihypertensive treatment, smoking cessation
ounseling, and advice about dietary choices and physical
ctivity are also beneficial.
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Consensus Conference Report April 15, 2008:1512–24hat Are the Principles and Objectives of
reatment of Lipoprotein Abnormalities?
yslipoproteinemia implies the presence of an increased
umber of atherogenic lipoproteins and/or a reduced pro-
ective capacity of HDL beyond what is considered optimal.
t is present when levels of triglycerides are high, HDL
holesterol is low, and/or there is atherogenic particle
xcess, such as high LDL cholesterol or an increased
umber of small LDL particles. Cut points have been
eveloped to define values associated with increased CVD
isk. However, these cut points are arbitrary because the
elationship of each of these measures with cardiovascular
vents is continuous and because the lipoprotein fractions
re metabolically connected in a complex fashion.
DL Cholesterol
here is widespread consensus (54,56,57) that for patients
ith elevated CMR, the primary objective in reducing risk
or CVD events through modification of lipid and lipopro-
ein risk factors is to lower LDL cholesterol values. This
onsensus is driven by the evidence that LDL is an
mportant component of the atherogenic process and that
reatments that lower LDL cholesterol have been convinc-
ngly demonstrated to reduce risk of CHD and stroke. The
ajor issues to be considered in translating this paradigm
nto practice are as follows: 1) At what LDL cholesterol
evel should treatment be initiated? 2) Through what
echanisms should LDL cholesterol be lowered? 3) Is LDL
holesterol the best measure to assess the response to
reatment? 4) What are the goals of treatment?
etermining cut points for initiating therapy. Based on
he curvilinear relationship between LDL cholesterol and
HD in the general population, from a public health
tandpoint it has been suggested that LDL cholesterol
alues 100 mg/dl are optimal. Lifestyle recommendations
argeted at reduction of saturated and trans unsaturated fat
nd cholesterol intake, lowering of excess body weight, and
ncreasing intake of soluble fiber should be emphasized as
rst-line therapy for those with LDL cholesterol values
100 mg/dl. It is clear that the absolute benefit that can be
chieved by LDL cholesterol lowering is proportional to the
nderlying global risk for CVD in a given individual. Thus,
uidelines for initiating both medical nutrition therapy as
ell as pharmacologic treatment aimed at LDL cholesterol
owering have been stratified by level of risk (54).
The panel agrees with the general recommendations to
tart lifestyle and pharmacologic therapy concurrently in
ubjects with CVD (secondary prevention) and in those
ith diabetes and multiple CVD risk factors, regardless of
aseline LDL cholesterol. In addition, we recommend
harmacologic therapy for moderately high-risk primary
revention patients (those with two or more CMR risk
actors and a 10-year risk 10%) if LDL cholesterol levels memain 100 mg/dl after several months of lifestyle
hanges.
herapeutic options for LDL cholesterol lowering. With
espect to dietary principles, the standard recommendations
or LDL cholesterol lowering have focused on lowering
aturated and trans fat to 7% of calories and dietary
holesterol to 200 mg/day, lowering excess body weight
y at least 5–10%, and increasing soluble fiber consumption.
n addition, increasing plant sterol and stanol intake mod-
stly lowers LDL cholesterol. Weight reduction and weight
aintenance are best achieved by a combination of caloric
eduction and increased physical activity.
As a result of the strong evidence base for the benefits of
tatin treatment on CVD outcomes, this class of drugs
rovides the primary pharmacologic modality for LDL
holesterol lowering. Although statins’ beneficial effects are
hought to be mediated predominantly through lowering of
DL cholesterol, their effects on HDL cholesterol and
ossibly other lipoproteins explain some of their benefit, and
he possibility of nonlipoprotein-mediated (pleiotropic) ef-
ects cannot be excluded. However, significant CVD benefit
as been directly linked to LDL cholesterol lowering using
ther modalities of treatment including diet, bile acid
equestrants, and ileal bypass surgery.
For patients who cannot tolerate a statin, or in whom
aximal dose statin therapy does not achieve treatment
oals, other LDL cholesterol-lowering drugs include
zetimibe, bile-acid sequestrants, or niacin. As mono-
herapy, these drugs are less effective at lowering LDL
holesterol than statins, but each enhances the LDL-
owering effect of statins. Bile-acid binding drugs, when
sed alone, can aggravate the dyslipidemia seen with insulin
esistance by increasing triglycerides (58). Bile-acid resins in
ombination with a statin or nicotinic acid with a statin
electively decrease small dense LDL particles (59).
ssessing response to therapy. LDL cholesterol is the
stablished primary target of treatment. In patients with
ypertriglyceridemia or the metabolic syndrome, the ATP
II (54) introduced non-HDL cholesterol as a secondary
reatment target, recognizing that in this patient population,
DL cholesterol underestimates the burden of atherogenic,
holesterol-carrying lipoproteins. Non-HDL cholesterol
dds no additional expense to a lipid profile and is easy to
alculate, but use of the measure has not been widely
dopted.
Although numerous studies have affirmed the superiority
f non-HDL cholesterol over LDL cholesterol as a marker
f CVD risk in patients with combined hyperlipidemia
elevated triglycerides and LDL cholesterol) or in those
ith a propensity for small dense LDL particles (patients
ith multiple CMR factors), both measures essentially
ocus on cholesterol as the agent of atherogenic risk.
owever, the measurement of cholesterol is a surrogate
easure of atherogenic risk, given that atherosclerosis is the
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April 15, 2008:1512–24 Consensus Conference Reportesult of a complex interaction between lipoproteins and the
essel wall.
Measurements of apoB or LDL particle number by
MR may more closely quantitate the atherogenic lipopro-
ein load. Some studies suggest that both are better indices
f CVD risk than LDL cholesterol or non-HDL choles-
erol and more reliable indexes of on-treatment residual
VD risk (26,27,36,37,42,60–67). ApoB and LDL particle
umber also appear to be more discriminating measures of
he adequacy of LDL-lowering therapy than are LDL
holesterol or non-HDL cholesterol. Statins lower non-
DL cholesterol more than they lower apoB (37), and
everal studies have shown that reaching the apoB target
sually requires more intensive therapy than achieving the
quivalent level for non-HDL cholesterol (68,69). ApoB
nd LDL particle concentration also appear to be more
losely associated with obesity, diabetes, insulin resistance,
nd other markers of CMR than are LDL cholesterol or
on-HDL cholesterol (70–72).
When both non-HDL cholesterol and apoB are mea-
ured, the two are highly correlated but only moderately
oncordant (35,47,65,68,73,74). Although a change in non-
DL cholesterol is closely related to a change in apoB, at
ny given level of non-HDL cholesterol there will be
onsiderable variation in apoB levels and vice versa, indi-
ating that the correlation is of limited clinical value for
ssessing individual risk. This lack of concordance is par-
icularly marked in patients with elevated triglyceride levels,
common finding in patients with CMR.
The consensus panel concludes that routine calculation
nd use of non-HDL cholesterol constitute a better index
han LDL cholesterol for identifying high-risk patients.
hat does not mean, however, that LDL cholesterol should
ot be measured and used to guide therapy. The many years
f public and professional education geared toward mea-
urement of LDL cholesterol has resulted in its successful
ntegration into the fabric of CVD prevention and treat-
ent, and it would be a mistake to discontinue its use. On
he other hand, the calculation of non-HDL cholesterol
hould be provided on all laboratory reports and should also
e used to ascertain risk in patients with low to moderate
DL cholesterol levels (i.e., LDL cholesterol 130 mg/dl).
able 1. Suggested Treatment Goals in Patients With CMR an
ighest-risk patients, including those with 1) known CVD or 2) diabetes plus
one or more additional major CVD risk factor
igh-risk patients, including those with 1) no diabetes or known clinical CVD
but two or more additional major CVD risk factors or 2) diabetes but not
other major CVD risk factors
ther major risk factors (beyond dyslipoproteinemia) include smoking, hypertension, and familyecause apoB appears to be a more sensitive index of aesidual CVD risk when LDL cholesterol or non- HDL
holesterol are 130 mg/dl or 160 mg/dl, respectively,
easurement of apoB, using a standardized assay, is war-
anted in patients with CMR on pharmacologic treatment.
n particular, apoB levels should be used to guide adjust-
ents of therapy. While LDL particle number as measured
y NMR appears equally informative as apoB, the concerns
xpressed above with regard to this assay limit its wide-
pread adoption at this time.
reatment goals for adults with CMR and lipoprotein
bnormalities. By definition, patients with CMR have
igh lifetime risk for CVD. Among patients with CMR and
ipoprotein abnormalities, there are patients whom we
efine as at highest risk for CVD over the short or
ntermediate term: those with known clinical CVD and
hose who do not have clinical CVD but who have diabetes
nd one or more other CMR factors beyond their dyslipi-
emia. We recommend that these highest-risk individuals
e treated to an LDL cholesterol goal 70 mg/dl, a
on-HDL cholesterol goal 100 mg/dl, and an apoB goal
80 mg/dl.
Among patients with CMR and lipoprotein abnormali-
ies, there are patients whom we define as high (but not
ighest) risk over the short or intermediate term: those
ithout diabetes or clinical CVD but with two or more
ajor CVD risk factors such as smoking, hypertension, and
amily history of premature CAD and those with diabetes
ut no other CMR risk factors. We recommend that these
igh-risk individuals be treated to an LDL cholesterol goal
100 mg/dl, a non-HDL cholesterol goal130 mg/dl, and
n apoB goal 90 mg/dl.
These treatment goal recommendations (Table 1) rep-
esent the panel’s consensus based on evaluation of the
vailable evidence. As is the case with any treatment
ecommendations, clinicians should recognize that indi-
idual patient factors and preferences may reasonably lead
o alteration of these goals (to higher or lower levels) in
ome patients. These factors might include age, life
xpectancy, desire for pregnancy in the near future in
omen, severity of risk factors, medication interactions,
nd provider and patient assessment of individual risks
oprotein Abnormalities
Goals
LDL Cholesterol
(mg/dl)
Non-HDL Cholesterol
(mg/dl)
ApoB
(mg/dl)
70 100 80
100 130 90
of premature CAD.d Lip
historynd benefits of treatment.
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levated triglyceride and reduced HDL cholesterol levels
re the most common abnormalities of the standard lipid
rofile in subjects with obesity and insulin-resistance–
elated CMR. Although increased triglycerides are mod-
stly associated with increased CVD risk, especially in
omen (75), it has been difficult to demonstrate that
owering of triglyceride levels is independently associated
ith a reduction in CVD events. While the HDL
holesterol level is a powerful risk predictor, the clinical
rial evidence supporting treatment of low HDL choles-
erol values is modest compared with that for LDL
holesterol lowering. For these reasons, approaches di-
ected at lowering triglyceride-rich lipoproteins and rais-
ng reduced HDL cholesterol levels have been assigned
econdary levels of therapeutic importance.
For subjects with mildly or moderately elevated triglyc-
ride levels (200 mg/dl), we support the ATP III recom-
endations to target LDL cholesterol first and then use
on-HDL cholesterol as a secondary target for treatment,
ith a goal 30 mg/dl higher than the patient’s LDL
holesterol goal, but we further recommend that the
opulation- equivalent apoB goal be reached. The exception
o not targeting triglycerides initially is the relatively small
roportion of patients with severe hypertriglyceridemia in
hom the initial treatment priority is to reduce the risk of
ancreatitis by combining dietary fat restriction with fibrate,
iacin, or high-dose n-3 fatty acid therapy. All patients with
ow HDL cholesterol should receive lifestyle counseling
ocusing on weight reduction, increased physical activity,
voidance of very high carbohydrate diets, and discontinu-
ng smoking.
A statin is the initial drug of choice for the vast majority
f people with CMR who have elevated triglycerides and
ow HDL cholesterol. In individuals on statin therapy who
ontinue to have low HDL cholesterol or elevated non-
DL cholesterol, especially if apoB levels remain elevated,
ombination therapy is recommended. The preferred agent
o use in combination with a statin is nicotinic acid because
here is somewhat better evidence for reduction in CVD
vents with niacin, as monotherapy or in combination, than
here is for fibrates. Nicotinic acid decreased CVD in the
oronary Drug Project (76) and total mortality in extended
ollow-up (77). Nicotinic acid in combination with a bile-
cid binding resin or a statin was associated with regression
f atherosclerosis and reduced CVD events in several studies
78–81). Although nicotinic acid has been associated with
nsulin resistance, in diabetes the use of low-dose nicotinic
cid (1,500 mg/day) does not significantly increase A1C
evels (82,83).
Fibrates have been shown to reduce CVD events in some
tudies but not mortality. In the Fenofibrate Intervention
nd Event Lowering in Diabetes (FIELD) trial of patients
ith type 2 diabetes, the primary outcome of overall CHDvents was not significantly reduced by the drug. The wecondary outcome of nonfatal MI was decreased by 24% (P
0.01), but fatal MI increased by 19% (P  0.22) (84).
imilar decreases in nonfatal MI, but not fatal MI or total
ortality, were seen in the WHO trial with clofibrate (85),
n the Helsinki Heart Study with gemfibrozil (86), in the
A-HIT trial with gemfibrozil (87), and in the Bezafibrate
nfarction Prevention (BIP) trial with bezofibrate (88).
n-3 fatty acid therapy lowers plasma triglyceride levels at
igh doses (4 g/day) and may be another option to
onsider to lower non-HDL cholesterol in patients on statin
herapy, but CVD outcome data are lacking for hypertri-
lyceridemic patients treated with these doses of n-3 fatty
cids. In diabetic subjects, enhanced glycemic control may
mprove lipid and lipoprotein abnormalities, particularly
ypertriglyceridemia. Specific antihyperglycemic agents
ay have advantages in this respect. For example, met-
ormin has modest triglyceride-lowering properties. Both
eroxisome proliferator-activated receptor- agonists in-
rease LDL particle size, but they have differing effects on
ther lipoprotein fractions. Pioglitazone raises HDL cho-
esterol to a greater extent than rosiglitazone and lowers
riglycerides, while rosiglitazone leads to a modest increase
n triglycerides. Furthermore, pioglitazone lowers whereas
osiglitazone increases LDL particle number (89).
hat New Information Would Help
mprove Lipoprotein Management?
esidual Risk on Statin Therapy
hile statin therapy has proven to reduce cardiovascular
isk, there remains substantial residual risk in treated pa-
ients. Studies are needed to determine whether very low
DL cholesterol levels are beneficial and safe and to define
hich types of patients receive the most benefit. We need to
etermine whether residual risk can be decreased by inter-
entions that impact other lipoproteins, such as increasing
DL cholesterol or decreasing small dense LDL. In addi-
ion, studies are needed to directly determine whether apoB
r other lipoproteins are better therapeutic targets than
DL cholesterol.
riglycerides
lthough patients with elevated triglycerides are at in-
reased CVD risk, there is a lack of data regarding the
enefits of strategies directly targeting elevated triglyceride
evels. Therefore, it is unclear whether or at what level
riglycerides should be treated and what should be the goal
f therapy. This will not be an easy question to answer
ecause of the complexities of triglyceride and lipoprotein
etabolism (90).
DL Cholesterol
n observational studies, low HDL cholesterol is a powerful
isk factor for CVD and remains a risk factor even in
atients with low LDL cholesterol. Because a recent trial
ith a cholesteryl ester transfer protein inhibitor to raise
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April 15, 2008:1512–24 Consensus Conference ReportDL cholesterol was terminated as a result of excess
ardiovascular events, it remains unclear whether raising
DL cholesterol per se reduces cardiovascular risk (91). It
ay be that increasing HDL cholesterol by modifying the
everse cholesterol pathway would paradoxically increase
isk, while other mechanisms to increase HDL cholesterol
ay lead to a reduction in risk. Strategies to safely and
ffectively raise HDL cholesterol remain a promising area of
esearch that is particularly relevant to CMR patients whose
yslipoproteinemia is often characterized by low levels of
DL cholesterol.
ombination Therapy
onotherapy with statins, fibrates, niacin, and bile acid
equestrants has been shown to reduce cardiovascular events
n clinical trials, but there is not yet robust evidence for
ncremental benefits or risks of combination therapy com-
ared with those of monotherapy. Results of ongoing and
uture trials of statin-niacin, statin-fibrate, and statin–n-3
atty acids will, it is hoped, help answer these questions.
enefits of Lipoprotein Management
n Other High-Risk Subsets
lthough statin therapy is highly effective in reducing CVD
isk in primary and secondary prevention, there remain
ubsets of patients regarding whom more data are needed.
hese include the elderly, those with chronic kidney disease,
nd young patients with CMR.
tility of Biomarkers
iomarkers such as CRP have been shown to identify
atients at higher risk for CVD events. However, their
dditive value as a clinical tool is unclear, especially among
atients with CMR (92). At least one ongoing trial (93) is
ddressing the issue of whether prospectively selecting
atients based on an elevated CRP will identify a high-risk
roup that will benefit from statin treatment.
ummary
atients with cardiometabolic risk factors represent a group
t high lifetime risk for CVD. These patients frequently
ave dyslipoproteinemia (low HDL cholesterol, increased
riglycerides, and/or an increased number of small LDL
articles). We recommend an assessment of global risk
ollowed by a multifactorial risk reduction strategy for such
ndividuals targeting each risk factor and emphasizing both
ifestyle and pharmacologic therapy. In terms of dyslipopro-
einemia, we recommend the following:
Statin therapy for the majority of dyslipoproteinemic
adult patients with CMR
For patients with CMR on statin therapy, guiding
therapy with measurements of apoB and treatment to
apoB goals in addition to LDL cholesterol and non-
HDL cholesterol assessmentsTreatment goals, summarized in Table 1, that address
the high lifetime risk of patients with dyslipoproteinemia
and CMR.
Clinical trials to determine whether the pharmacologic
therapy required to achieve very low levels of atherogenic
lipoproteins is safe and cost-effective
A concerted, multifaceted, public health effort, focused
on lifestyle modification, to reduce mean population
levels of atherogenic lipoproteins to values well below
current ones.
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